Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management

Area of Science:

• Nephrology
• Transplantation Immunology

Background:

• Membranous nephropathy (MN) is a leading cause of nephrotic syndrome post-transplant, increasing allograft loss risk.
• MN can recur or appear as a de novo disease, often linked to antiphospholipid A2 receptor antibodies.
• Post-transplant MN exhibits unique characteristics, such as reduced spontaneous remission and higher need for immunosuppression.

Purpose of the Study:

• To review the pathophysiology of post-transplant MN.
• To address key issues like antiphospholipid A2 receptor antibody prognostic value, living-related donation risks, and de novo MN-rejection links.
• To propose a comprehensive management algorithm for kidney transplant recipients with MN.

Main Methods:

• Literature review and synthesis of existing studies on post-transplant membranous nephropathy.
• Analysis of pathophysiology, clinical course, and therapeutic strategies.
• Development of a proposed management algorithm based on current evidence.

Main Results:

• Post-transplant MN recurrence is associated with antiphospholipid A2 receptor antibodies but has a poorer prognosis than primary MN.
• Limited data exists on rituximab efficacy in this population, highlighting a need for further research.
• Unresolved issues include the prognostic role of antibodies, risks with living donors, and MN-rejection interactions.

Conclusions:

• A structured approach is needed for managing MN in kidney transplant patients.
• Further research is required to clarify treatment efficacy and optimize patient outcomes.
• The proposed algorithm aims to guide pre-transplant evaluation, post-transplant monitoring, and recurrence management.